EFSA Clears β-NMN – What the Positive Safety Opinion Means for Supplement Brands

EFSA issued a positive safety opinion on EffePharm’s β-NMN in Q2 2026, opening the EU novel food authorisation pathway for this popular NAD+ precursor supplement. Full EC authorisation is still pending Official Journal publication, so NMN remains technically unauthorised in the EU — brands already selling it into European markets should review their compliance exposure now.